Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% |
|
-7.89% | -28.57% |
Jul. 01 | Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine | MT |
Jul. 01 | New semester, new state of mind | ![]() |
Sales 2024 * | 178M 194M | Sales 2025 * | 235M 257M | Capitalization | 478M 521M |
---|---|---|---|---|---|
Net income 2024 * | - 0 | Net income 2025 * | -45M -49.07M | EV / Sales 2024 * | 3.01 x |
Net Debt 2024 * | 55.78M 60.83M | Net Debt 2025 * | 86.36M 94.18M | EV / Sales 2025 * | 2.4 x |
P/E ratio 2024 * |
125
x | P/E ratio 2025 * |
-37.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
0.29% | Free-Float | 83.51% |
Latest transcript on Valneva SE Pref.
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 13-05-09 | |
Peter Buhler
DFI | Director of Finance/CFO | 54 | 21-07-28 |
Vincent Dequenne
COO | Chief Operating Officer | - | 21-07-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kathrin Jansen
BRD | Director/Board Member | - | 23-06-20 |
James Sulat
BRD | Director/Board Member | 73 | 13-03-06 |
Jim Connolly
BRD | Director/Board Member | 59 | 22-06-23 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- VLA Stock
- VLAP Stock